Abstract
Background Body-worn, inertial sensors can provide many objective measures of balance and gait. However, the objective measures that best reflect patient perception of mobility disability and clinician assessment of Parkinson disease (PD) are unknown.
Objective The purposes of this study were: (1) to determine which objective measures of balance and gait are most related to patient perception of mobility disability and disease severity in people with PD and (2) to examine the effect of levodopa therapy on these correlates.
Design This was an experimental correlation study.
Methods One hundred four people with idiopathic PD performed 3 trials of the Instrumented Stand and Walk Test (ISAW) in the “on” and “off” medication states. The ISAW consists of quiet standing (30 seconds), gait initiation, straight walking (7 m), and turning (180°), yielding 34 objective measures of mobility from body-worn inertial sensors. Patient perception of mobility disability was assessed with the Activities-specific Balance Confidence (ABC) scale and the mobility subscale of the Parkinson's Disease Questionnaire (PDQ-39). Disease severity was assessed with the Unified Parkinson's Disease Rating Scale, part III (motor UPDRS). Spearman correlations were used to relate objective measures of mobility to patient perception and disease severity.
Results Turning speed, gait speed, and stride length were most highly correlated to severity of disease and patient perception of mobility disability. The objective measures of mobility in the off-medication state were more indicative of patient perception of mobility disability and balance confidence compared with on-medication state measures.
Limitations Causation is an inherent problem of correlation studies.
Conclusion Physical therapists should evaluate mobility in people with PD in the off-medication state because the off-medication state is more related to disease severity and patient perception of mobility disability than the on-medication state mobility. Assessment and treatment of mobility in people with PD should target specific measures (ie, turning, gait speed, and stride length) because these measures best reflect patients' quality of life and balance confidence.
Footnotes
All authors provided concept/idea/research design. Dr Curtze, Dr Nutt, Dr Carlson-Kuhta, and Dr Horak provided writing. Dr Carlson-Kuhta, Dr Mancini, and Dr Horak provided data collection. Dr Curtze and Dr Mancini provided data analysis. Dr Carlson-Kuhta and Dr Horak provided project management. Dr Horak provided fund procurement and facilities/equipment. Dr Nutt provided participants. Dr Nutt, Dr Carlson-Kuhta, Dr Mancini, and Dr Horak provided consultation (including review of manuscript before submission).
The study protocol was approved by the Oregon Health & Science University Institutional Review Board.
This publication was made possible with support from a grant from the National Institute on Aging (AG006457); a Challenge Grant from the National Institute of Neurological Disorders and Stroke (RC1 NS068678) and the Oregon Clinical and Translational Research Institute (OCTRI) at OHSU; and grant number UL1 RR024140 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and NIH Roadmap for Medical Research.
The OHSU and Dr Horak have a significant financial interest in APDM Inc, a company that may have a commercial interest in the results of this research and technology. This potential institutional and individual conflict has been reviewed and managed by OHSU.
- Received December 1, 2015.
- Accepted April 27, 2016.
- © 2016 American Physical Therapy Association